Roflumilast cream?

Roflumilast is a PDE-4 inhibitor. The oral form (Daliresp) is approved for COPD. A topical (cream) form of roflumilast has been studied, but it is not currently an FDA-approved or widely available product in the US or EU.

What this means in practice:
- There is no roflumilast cream you can routinely prescribe or buy as an approved treatment right now.
- Topical roflumilast has been evaluated in clinical trials for inflammatory skin conditions such as atopic dermatitis (eczema) and psoriasis. Some studies showed benefit, but development has not led to an approved product to date.
- If/when a roflumilast cream reaches the market, it would be regulated similarly to other topicals, with information on approved indications, dosing, efficacy, and safety.

Possible side effects (based on topical PDE-4 inhibitors studied in skin):
- Local skin reactions at the application site (burning, itching, redness, irritation)
- Very rarely the patient might notice more systemic effects if there is substantial absorption, but topical exposure is typically lower than oral.

If you’re considering options for a skin condition:
- There are approved topical PDE-4 inhibitors for eczema, such as crisaborole (Eucrisa).
- Other common options include topical corticosteroids and calcineurin inhibitors, depending on the condition and severity.
- Moisturizers and skin care routines are also important adjuncts.

Would you like me to check the latest status for your country or for a specific condition (e.g., atopic dermatitis vs. psoriasis)? I can pull up recent trial updates or regulatory status if you tell me your location.